Summary of SAVIENT PHARMACEUTICALS INC

Item 8.01. Other Events.

On October 7, 2009, Savient Pharmaceuticals, Inc. (the "Company") announced its intention to commence, subject to market and other conditions, an underwritten public offering of 4,000,000 shares of the Company's common stock, $0.01 par value per share (the "Offering"). The Company also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 600,000 shares of common stock to cover over-allotments, if any. The Offering is being made pursuant to a shelf registration statement that the Company filed with the Securities and Exchange Commission on September 24, 2007 and that became effective on October 10, 2007 (Registration No. 333-146257). All of the shares in the Offering are to be sold by the Company. J.P. Morgan Securities Inc. is acting as sole book-running manager of the Offering. Wedbush PacGrow Life Sciences is also acting as a lead manager of the Offering.

The Company's press release dated October 7, 2009 announcing the Offering is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The Company is also filing this Current Report on Form 8-K for the purpose of filing the Company's Certificate of Incorporation, as amended, as Exhibit 3.1 hereto and updating its risk factors, which are filed as Exhibit 99.2 to this Current Report and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.      Description
3.1              Certificate of Incorporation of the Company, as amended, filed as
                 Exhibit 3.1 to the Company's Form S-3 (Registration No.
                 333-146257) filed on September 24, 2007, is incorporated herein
                 by reference.
99.1             Press Release of the Company dated October 7, 2009.
99.2             Risk Factors of the Company.